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Abstract
Background: Yiqifumai is a traditional Chinese medicine compound preparation used for treatment of
microcirculatory disturbance-related diseases in China. We have previous reported that pretreatment with Yiqifumai
could improve the lipopolysaccharide (LPS) -induced microcirculatory disturbance in rat mesentery. The present
study intended to investigate the effect of pretreatment with Yiqifumai on intestine injury and survival rate of the
rats subjected to LPS challenge.
Methods: Male Wistar rats were continuously infused with LPS (5 mg kg-1 body weight h-1) via the left jugular vein
for 90 min. In some rats, Yiqifumai 80 (mg/kg) was administrated through the left jugular vein 10 min before LPS
infusion. The mean arterial pressure (MAP), heart rate (HR), rectal temperature (RT), respiratory rate (RR) and survival
rate were measured at 24 h, 48 h and 72 h after LPS infusion. At 72 h after exposure to LPS, the intestine
morphology was observed under a stereomicroscope and the immunohistochemistry staining of intestine was
conducted to evaluate the expression of intercellular adhesion molecule 1 (ICAM-1) and the number of
myeloperoxidase (MPO) positive cells in tissue. After observation of intestine microcirculation, blood was collected
from the abdominal aorta of each animal to analyze the level of inflammatory markers in plasma, including TNF-a
and MCP-1.
Results: Compared to the control, LPS infusion significantly decreased MAP and the survival rate and increased the
HR, RT and RR, as well as elicited leukocyte infiltration, intestine hemorrhage, enhanced expression of ICAM-1 and
raised level of inflammatory markers. All of indicators, except for the RT, were significantly attenuated by Yiqifumai,
in contrast to the LPS group.
Conclusions: The results demonstrated the potential of pretreatment with Yiqifumai to ameliorate rat intestine
injury, inflammatory response to LPS and the decrease in survival rate caused by LPS challenge.
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Background
Despite decades of efforts and significant advances in
antimicrobial therapy and overall medical care, sepsis is
still among the leading causes of death in noncardiac
intensive care units, the mortality reaching to 35% in US
[1] and up to 50% in China for the severe sepsis [2].
Therefore, management of sepsis remains a challenge
for clinician.
Sepsis is associated with deleterious functional and
structural changes in various organs, including gastro-
intestinal tract. Manifestations of gram-negative sepsis
and septic shock are triggered by lipopolysaccharide
(LPS), a component of the outer cell wall of gram-
negative bacteria [3], which has long been recognized
to give rise to a variety of inflammatory response as
well as microcirculatory disturbance. Sepsis may relate
to the impairment of microcirculation that compro-
mises local oxygen delivery [4]. Thus, strategies
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potentially able to attenuate microcirculation disorders
during sepsis may improve outcome.
Yiqifumai is a newly developed injection of traditional
Chinese medicine that was approved in 2007 by the
China State Food and Drug Administration for treat-
ment of microcirculatory disturbance-related diseases,
such as coronary heart disease, cerebrovascular disease
extensively, in China. Yiqifumai consists of the water-
soluble compounds of Radix Ginseng (RG), Raidix
Ophiopogonis (RO) and Fructus Schisandra (FS). Avail-
able evidence revealed that components of Yiqifumai are
effective for prevention and recovery of shock, ischemic
and oxidative damage in the brain during heatstroke [5],
able to protect against heat stroke-induced arterial
hypotension and cerebral ischemia by inhibition of indu-
cible nitric oxide synthase (iNOS)-dependent nitric
oxide (NO) overproduction in the brain and excessive
accumulation of inflammatory cytokines in the periph-
eral blood [6]. Our previous study demonstrated that
administration of Yiqifumai could inhibit the leukocyte
adhesion to venular wall, the degranulation of mast cell
in vivo, the hydrogen peroxide (H2O2) release and the
expression of adhesion molecule CD11b/CD18 in neu-
trophils stimulated by LPS [7]. It would be interesting to
know whether or not the capacity of Yiqifumai to
attenuate microcirculatory disturbance induced by intes-
tine injury may ultimately benefit the outcome of the
affected animals. The present study demonstrated the
potential of Yiqifumai to improve the insults on rat
imposed by infusion of LPS, including the disturbance
in vital signs, the injury on intestine and the decrease in
survival rate, providing further and more relevant evi-
dence for the clinic use of Yiqifumai.
Methods
Reagents
LPS (Escherichia Coli serotype O55:B5) was obtained
from Molecular Probes, Ltd (Eugene, OR, USA). Hae-
molysin were purchased from BD Biosciences Immuno-
cytometer Systems (San Jose, CA, USA). MCP-1 and
TNF-a ELISA kits were purchased from R&D Systems
(Minneapolis, MN), Assay Designs (Ann Arbor, MI) or
eBioscience (San Diego, CA).
Yiqifumai was obtained from Tasly Pharmaceutical
Co. ltd (Tianjin, China). The lot number of the drug
used in this experiment was 20070702 with a package of
0.65 g per ampoule, 1 g of Yiqifumai containing 6.3 mg
of gensenoside (ingredient of RG), 253.6 mg of polysac-
charides (ingredient of raidix ophiopogonis), and 0.2 mg
of schizandrin (ingredient of FS) [7]. No any steroid was
included in the content of Yiqifumai. The compound
was dissolved in saline to a concentration of 80 mg/ml
before use.
Animals
Male Wistar rats weighing 200~250 g were obtained
from the Animal Center of Peking University Health
Science Center. The rats were fed a standard laboratory
chow diet and maintained at 24 ± 1°C, relative humidity
50% ± 1% with a 12-h-12-h light-dark cycle. The ani-
mals were fasted for 12 h before the experiment, allow-
ing free access to water. All animals were handled
according to the guidelines of the Peking University
Animal Research Committee.
Administration of LPS and Yiqifumai
In the control group (control), 1 mL saline was injected
via the left jugular vein within 1 min. Saline (6 mL kg-1
body weight h-1) was continuously infused 10 min later
through the left femoral vein for 90 min.
In the LPS group (LPS), 1 mL saline was injected via the
left jugular vein within 1 min, and LPS in saline was con-
tinuously infused 10 min later through the left femoral
vein for 90 min at a dose of 5 mg kg-1 body weight h-1.
In the Yiqifumai plus LPS group (Yiqifumai+LPS), Yiqifu-
mai saline solution (80 mg kg -1 body weight) was injected
via the left jugular vein within 1 min, and LPS in saline was
continuously infused 10 min later through the left femoral
vein for 90 min at the same dose as in LPS group.
A total of 54 rats were included and randomly distrib-
uted into Control, LPS and Yiqifumai+LPS groups, 18
animals for each. The mean arterial pressure (MAP),
heart rate (HR), rectal temperature (RT), respiratory rate
(RR) and survival rate were estimated every 24 h. The
examinations on intestine hemorrhage, histology and
immunohistochemistry were performed at 72 h after
LPS infusion on the survival animals in each group.
Physiological parameters and survival rate
The physiological parameters were monitored at 24 h,
48 h and 72 h after the LPS infusion. Both MAP and
HR were monitored with an intellectual non-invasive
hemomanometer (BP-98A, Softron, China). RT was
monitored by a thermocouple (ME04008, Bowdoinham,
USA), and RR was counted and recorded simulta-
neously. At each time point, the number of survival ani-
mals was registered and the survival rate was calculated.
Detection of hemorrhage in intestine
Surgical procedure was performed as previously
described [7]. The rats were anesthetized with urethane
(1.25 mg kg-1 body weight) by intramuscular injection.
The jugular vein and femoral vein were cannulated for
injection with various reagents. For the rats that sur-
vived 72 h of LPS infusion, the abdomen was opened
via a midline incision of 20-30 mm in length and ileoce-
cal portion of the intestine was gently exteriorized and
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mounted on a transparent plastic stage. The intestine was
kept warm and moist by continuous superfusion with sal-
ine solution at 37°C. The intestine were observed under a
stereomicroscope (SZ-CTV, Olympus, Japan). Camera
(Jk-TU53H, Toshiba, Japan) mounted on the microscope
transmitted the images onto a color monitor (J2118A,
TCL, China), and the images were recorded with a DVD
(DVR-R25, Malata, China). For each animal, five intestine
areas were randomly selected for observation, each of
which involved five arteries and five veins that were par-
allel to each other and without bend [8-12]. The number
of hemorrhagic spots was scored and presented as the
mean of three measurements at an area
Histologic and immunohistochemical examination of the
intestine
At 72 h after exposure to LPS, 2 cm ileocecal portion of
intestine was isolated and fixed with 10% buffered for-
malin. The samples were further processed as routine,
and mounted sections were stained with hematoxylin
and eosin for light microscopy. For immunohistochem-
ical assessment, the sections were incubated with either
mouse anti-intercellular adhesion molecule 1 (ICAM-1)
(BD Biosciences Pharmingen, 1:400) or rabbit anti-mye-
loperoxidase (MPO) (NeoMarkers, Fremont, CA,1:300)
overnight at 4°C, followed by incubation with biotiny-
lated donkey anti-rabbit or donkey anti-mouse IgG
(1:200) for 30 min. Positive staining was revealed by dia-
minobenzidine, according to the manufacture’s instruc-
tion of the ABC kit (Santa Cruz Inc.). The relative
integrated optical density of immunohistochemistry
staining of ICAM-1 in vascular endothelium was calcu-
lated with Imaging-Pro Plus 6.0[13]. Each lesion was
assessed by estimating the area of the objects and the
medium pixel intensity per object, as the integrated
optical density (IOD). The image background was set at
white (grayscale level = 255) for IOD calculations. The
number of MPO positive cells was counted within a
field of view under the microscope with a 20 × objective
lens and 5 fields were selected randomly in each section
with the same software.
Detection of inflammatory markers in plasma
After observation of intestine microcirculation, blood was
collected from the abdominal aorta of each animal and
anticoagulated with heparin (20 unit/ml blood). The
plasma was isolated by centrifugation. Fifty microliters of
plasma or standard was incubated with 50 μl capture
beads for 1 h at room temperature, and then mixed with
50 μl phycoerythrobilin (PE)-labeled TNF-a and MCP-1
detection antibodies and incubated for 2 h at room tem-
perature to form a sandwich complex. Following incuba-
tions, 1 ml of washing buffer (BD, Biosciences
Pharmingen, USA) was added to each tube, and the mean
fluorescence intensity was detected using flow cytometry
(FACSCalibur, B.D. Co, USA). The data were analyzed
with BD Cytometric Bead Array analysis software [10].
Statistical analysis
All values were presented as mean ± SE. Chi-square test
was applied to test for the significance of the difference
in the survival rate of various groups. For the remaining
parameters, the means of different groups were com-
pared by ANOVA and F-test. A value of P < 0.05 was
designed as significant.
Results
Survival rate and physiological parameters
Figure 1 shows the number of the survival rats at differ-
ent time points in the 3 groups. All rats in the control
group survived the 72 h observation, while the number
of survival animals in LPS group decreased linearly with
time and only 6 rats left at 72 h, representing a survival
rate of 33%. Pretreatment with Yiqifumai significantly
restored the survival rate of animals reduced by LPS
exposure, reaching to 89% at 48 h, and 67% at 72 h.
The time course of changes in MAP in different
groups is present Figure 2(A). Obviously, the value of
MAP in control group maintained almost unchanged
over the period of 72 h observation. By contrast, MAP
in LPS group significantly deceased at 24 h, and further
deteriorated until 72 h. Pretreatment with Yiqifumai sig-
nificantly attenuated MAP reduced by LPS infusion.
The time course of changes in HR under various condi-
tions is summarized in Figure 2(B) Similarly to MAP, the
value of HR in the control group kept nearly consistent
during the whole period of observation. LPS infusion eli-
cited an increase in HR at 24 h and 48 h and an impress-
ive decrease at 72 h. Pretreatment with Yiqifumai
remarkably attenuated the LPS-induced HR fluctuation.
Left panel of Figure 3 illustrates the changes of RR
with time in the three groups. The result demonstrated
that in control group, RR had no significant change
throughout the observation compared with baseline. In
the LPS infusion group, the RR increased from 24 h
after LPS infusion. Pretreatment with Yiqifumai signifi-
cantly attenuated the increase in RR by LPS.
The time course of changes in RT is presented in
Figure 3, right panel. Likewise, RT had no significant
changes in control group throughout the period of
observation compared with baseline. In the LPS infusion
group, RT increased significantly starting from 24 h
after LPS infusion. Pretreatment with Yiqifumai had no
significant influence on the increase in RT by LPS.
Intestine hemorrhage
Representative images of intestine are showed in upper
panel of Figure 4, which were taken by a stereomicroscope
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Figure 1 The effect of Yiqifumai on the number of the survival rats. Control: Control group; LPS: LPS group. Yiqifumai+LPS: Yiqifumai plus
LPS group. #P < 0.05 vs. Control group, †P < 0.05 vs. LPS group.
Figure 2 The effect of Yiqifumai on rat mean arterial pressure (A) and heart rate (B). Control: Control group; LPS: LPS group. Yiqifumai
+LPS: Yiqifumai plus LPS group. Data were expressed as mean ± SE. The number of animals examined at 0, 24, 48 and 72 h in each group were
18, 18, 18 and 18 for Control group, 18, 15, 12 and 6 for LPS group and 18, 16, 15 and 12 for Yiqifumai+LPS group, respectively. #P < 0.05 vs.
Control group, †P < 0.05 vs. LPS group.
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at 72 h after LPS infusion. In control group, few, if any,
hemorrhagic spots were observed (A1). However, LPS
infusion for 72 h gave rise to numerous hemorrhagic spots
in intestine (A2), which was attenuated apparently by pre-
treatment with Yiqifumai (A3). The lower panel of Figure
4 is a quantitative evaluation of the effect of pretreatment
with Yiqifumai on the hemorrhage in rat intestine elicited
by LPS challenge.
Histologic study of the intestine
Histologic examination on the intestine was carried out
72 h after LPS infusion, and the representative images
from different groups are presented in Figure 5. In
comparison with Control group (A), LPS infusion for
72 h resulted in apparent damages on the intestine
mucosa, including denudation of villi with exposed
dilated capillaries, lamina propria disintegration,
ulceration, and hemorrhage (B). Pretreatment with
Yiqifumai extenuated all the alterations induced by
LPS (C).
Immunohistochemical assessment on intestine
To assess the expression of ICAM-1 on microvascular
endothelium of intestine, immunohistochemical staining
was performed 72 h after LPS infusion. As noticed from
Figure 6, rare expression of ICAM-1 was detected on
microvascular endothelium of intestine in Control group
(A and D). In contrast, the immunochemical staining for
the expression of ICAM-1 was prominent in LPS group (B
and E), which was attenuated significantly by pretreatment
with Yiqifumai (C and F). This result was confirmed by a
quantitative evaluation, as showed in Figure 6.
As an indicative enzyme of neutrophil granulocytes,
MPO was revealed by immunohistochemical staining
72 h after LPS infusion on intestines to evaluate the leu-
kocyte infiltration. The representative images and the
quantifications of the MPO-positive cells in the three
groups are presented in Figure 7. The MPO-positive
cells was hardly detectable in Control group(A) but sig-
nificantly increased by LPS, indicative of leukocyte infil-
tration in this situation(B). Noticeably, the LPS elicited
Figure 3 Effects of Yiqifumai on rat respiratory rate (A) and rectal temperature (B). Control: Control group; LPS: LPS group; Yiqifumai+LPS:
Yiqifumai plus LPS group. Data were expressed as mean ± SE. The number of animals examined at 0, 24, 48 and 72 h in each group were 18,
18, 18 and 18 for Control group, 18, 15, 12 and 6 for LPS group and 18, 16, 15 and 12 for Yiqifumai+LPS group, respectively. # P < 0.05 vs.
Control group, †P < 0.05 vs. LPS group.
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increase in MPO-positive cells was significantly inhibited
by administration of Yiqifumai(C).
Determination of concentration of inflammatory markers
in plasma
The concentrations of the cytokines TNF-a and MCP-1
in plasma are presented in Figure 8. In the control
group, the concentrations of TNF-a and MCP-1 were
24.51 ± 5.57 and 22.72 ± 8.67 ng/l, respectively. The
concentrations of the two cytokines were enhanced dra-
matically by LPS stimulation to 493.97 ± 192.29 and
741.53 ± 126.86 ng/l, respectively. Treatment with Yiqi-
fumai inhibited the LPS-induced production of TNF-a
and MCP-1 markedly.
Discussion
The present study demonstrated that LPS continuous
infusion caused a range of disturbances in the vital signs
of rats, including the decrease in MAP and the increase
in HR, RT and RR, as well as raised the level of
inflammatory markers in plasma and reduced the survi-
val rate of the animals. Morphological examination
showed a significant increase in leukocyte infiltration,
hemorrhage and expression of ICAM-1 in intestine in
response to LPS infusion. Interestingly, all the LPS eli-
cited alterations, except for RT, were ameliorated atte-
nuated significantly by pretreatment with Yiqifumai.
LPS is responsible for the initiation of the septic cas-
cade in Gram-negative bacterial infections, which
involves upregulation of intercellular adhesion molecules
1 (ICAM-1) and production of large amount of cyto-
kines [14,15], the two processes that are both mediated
by NF-B and interplayed each other, cumulating to the
damage on the vascular endothelium [16-18]. Leuko-
cytes bind to the vessel through interaction with ICAM-
1 on the surface of the endothelium, these leukocyte-
endothelial interactions promote the release of reactive
oxygen species (ROS) and other mediators, which
destroy bacteria on one hand, but inflict damage on the
endothelium and cause exaggerated microvascular
Figure 4 The attenuating effect of Yiqifumai on LPS-induced rat intestine hemorrhage. A, representative images of the intestines from
different groups at 72 h after LPS infusion. In control group few hemorrhagic spots were observed (A1), numerous hemorrhagic spots in
intestine were observed at 72 h after LPS infusion (A2), which was attenuated apparently by pretreatment with Yiqifumai (A3). B, quantitative
evaluation of the effect of pretreatment with Yiqifumai on the hemorrhage in rat intestine elicited by LPS challenge. Data were expressed as
mean ± SE. The number of animals examined was 18 for Control group, 6 for LPS group and 12 for Yiqifumai+LPS group. Arrow indicates
hemorrhagic spot (a). # P < 0.05 vs. Control group, †P < 0.05 vs. LPS group.
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dysfunction on the other hand [19]. The endothelial per-
meability thus increases due to the structure damage of
the endothelial cells as well as to the enzymatic cleavage
of adherent junction proteins [20], which eventually
results in the transmigration of leukocytes across the
endothelial lining into the surrounding tissues and the
loss of fluid into extravascular space leading to hypoten-
sion and life-threatening edema in multiple organs [21].
It is known that the MPO activity was markedly relevant
to tissue neutrophil accumulation [22,23]. In this study,
the intestine tissue MPO activity was assayed to assess
the numbers of neutrophils recruited to the intestine tis-
sue. The sepsis-associated organ injury is further com-
plicated by the implication of overproduction of reactive
oxygen species [24,25]. Cytokines such as TNF-a and
MCP-1, which are believed to be pro-inflammatory fac-
tors, are produced by activated monocyte/macrophages,
and acts mainly to attract neutrophils and monocytes
[26]. These chemokines are all associated with the
influx, accumulation and activation of highly destructive
cells involved in local inflammatory processes. As Wang
has reported Shengmai San, which has similar ingredi-
ents with Yiqifumai, significantly reduced excessive
accumulation of inflammatory cytokines in the periph-
eral blood[5]. We have acquired the similar outcomes in
this study, Yiqifumai alleviated remarkably the overpro-
duction of inflammatory markers(TNF-a and MCP-1).
Owing to the complexity of the events in the course of
sepsis, it is unlikely that a single therapeutic agent, espe-
cially those that target the points downstream the net-
work, such as inhibition of inducible nitric oxide
synthase (iNOS)-dependent nitric oxide (NO) overpro-
duction, may overcome all the complications. It would
be desirable to have a regime that not only acts at the
crucial initial steps of sepsis but also has multi-targeting
potential. We have previously reported that pretreat-
ment with high-dose Yiqifumai (80 mg kg-1), compared
to low (15 mg kg-1) and medium (30 mg kg-1) dose
Figure 5 The effect of pretreatment with Yiqifumai on the histology of rat intestine. The morphology of intestine was examined 72 h
after LPS infusion. In Control group (A), intestine mucosa was lined by densely and regularly packed villi with continuous basement membrane.
No hemorrhage or swollen villus was observed. In LPS group (B), evident villus denudation (a) and swelling (b) was noted. Pretreatment with
Yiqifumai significantly ameliorated the LPS-induced intestine damage (C), although some villus denudations remained.
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group, significantly attenuates LPS-induced microcircu-
latory disturbance in rat mesentery, including reduction
in the number of adherent leukocytes, the intensity of
DHR fluorescence, degradation of mast cell, albumin
leakage, and the expression of CD11b/CD18, suggesting
that Yiqifumai is a promising regime for treatment of
LPS-evoked sepsis thanks to its multiple targeting
potential for the initial steps of the process [7]. The
results of the current study demonstrated this specula-
tion, showing that pretreatment with Yiqifumai signifi-
cantly ameliorates the outcome of the rats exposed to
LPS, exhibiting as the improvement of the vital signs,
attenuation of the intestine injury and the increase in
survival rate.
Figure 6 The attenuating effect of Yiqifumai on LPS-induced expression of ICAM-1 on microvascular endothelium of intestine. Ι,
representative images of the intestines from different groups at 72 h after LPS infusion. A and D: Control group, the expression of ICAM-1 was
hardly observed; B and E: LPS group, the expression of ICAM-1 was apparent (a); C and F: Yiqifumai+LPS group, the expression of ICAM-1
diminished significantly (b). ΙΙ, quantitative evaluation of the effect of pretreatment with Yiqifumai on expression of ICAM-1 on microvascular
endothelium of intestine. Data were expressed as mean ± SE. The number of animals examined was 18 for Control group,6 for LPS group and
12 for Yiqifumai + LPS group. #P < 0.05 vs. Control group, †P < 0.05 vs. LPS group.
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Figure 7 The improving effect of Yiqifumai on the number of MPO-positive cells in intestine. I, representative images for the effect of
pretreatment with Yiqifumai on the number of MPO-positive cells in intestine. Few MPO-positive cells were observed in rat intestine in Control
group (A). LPS infusion evoked numerous MPO-positive cells (B). The number of MPO-positive cells was reduced apparently by pretreatment with
Yiqifumai (C). Arrow indicates MPO-positive cell (a). II, quantitative evaluation of the effect of pretreatment with Yiqifumai on the number of
MPO-positive cells in intestine. Control: Control group; LPS: LPS group. Yiqifumai+LPS: Yiqifumai plus LPS group. Data were expressed as mean ±
SE. The number of animals examined was 18 for Control group, 6 for LPS group and 12 for Yiqifumai + LPS group. #P < 0.05 vs. Control group,
†P < 0.05 vs. LPS group.
Figure 8 The effect of Yiqifumai on the inflammatory markers concentration in plasma. Control: Control group; LPS: LPS group. Yiqifumai
+LPS: Yiqifumai plus LPS group. #P < 0.05 vs. Control group, †P < 0.05 vs. LPS group. The number of animals examined was 18 for Control
group, 6 for LPS group and 12 for Yiqifumai + LPS group.
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The beneficial effects found for Yiqifumai in the
present study may be attributed at least in part to RG,
one of the ingredients of Yiqifumai. We have previous
reported that Ginsenoside Rb1 (Rb1) and Ginsenoside
Rg1 (Rg1), whose chemical structure were presented
in Figure 9, the major active components of RG, could
both inhibit the leukocyte adhesion to venular wall
and the degranulation of mast cell in vivo, and Rg1
may attenuate the hydrogen peroxide (H2O2) release
and Rb1 attenuate the expression of adhesion mole-
cule CD11b/CD18 in neutrophils stimulated by LPS
[10]. We assume that it is these actions, together with
the finding in the current study that Yiqifumai inhibits
the expression of ICAM-1, that attenuate the recruit-
ment of leukocytes and endothelium dysfunction,
reduce the leukocyte infiltration and edema in the sur-
rounding tissues and subsequent organ injury. The
exact role of other two ingredients of Yiqifumai, RO
and FS, requires further identification, although the
advantage of using three ingredients over RG alone is
evident.
Conclusions
In summary, the study demonstrated that pretreatment
with Yiqifumai significantly improve the outcome of the
rats that were subject to LPS challenge, and this effect
may be associated with the actions that Yiqifumai
exerted on the pivotal initial points of the sepsis process.
This result provides further support for the use of Yiqi-
fumai as an adjuvant therapy for sepsis in clinic.
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